New light adjustable lenses results

Article

A small German study of light adjustable lenses (LALs) implanted in 10 eyes in 7 patients has produced positive results, according to the lens's manufacturer, Calhoun Vision.

A small German study of light adjustable lenses (LALs) implanted in 10 eyes in 7 patients has produced positive results, according to the lens's manufacturer, Calhoun Vision.

The LAL allows the doctor to adjust and refine the refraction following implantation using a Vision Light Delivery device, which is an ultra light system. Doctors are able to set the refractive correction to suit the specific visual needs of their patient prior to undertaking the final procedure to set the correction.

Published in the May issue of the Journal of Refractive Surgery the Klinik und Poliklinik für Augenheilkunde in Munich, Germany the initial results, at two weeks postoperatively, before the first light adjustment was made the mean refraction was +0.78 D, ±0.79 D. After the initial adjustment, the mean refraction improved to -0.07 D, ±0.21 D. Four eyes were treated with a second adjustment. At 1 month postoperative, all eyes were within ±0.50 D of the targeted refraction, with a mean uncorrected distance visual acuity of 1.02. All eyes gaining at least two lines of corrected distance visual acuity.

Results presented at ARVOA poster, which was presented by the Optics Laboratory of the University of Murcia and the Department of Ophthalmology at the University Hospital, Virgen de la Arrixaca, Murcia, Spain, at the recent ARVO meeting reported on monovision and asphericity results in patients implanted bilaterally with the LAL. In the monovision study, 8 patients had one eye adjusted for emmetropia with the fellow eye adjusted for myopia. The final mean refraction in the emmetropia eyes ranged from 0.00D to -0.75 D, and in the myopic eyes from -1.75 D to -2.25 D. The researchers pointed out that with the LAL, if a patient could not tolerate monovision, then the treatment could be reversed in the myopic eye and set to emmetropia – something that cannot be done with a non-adjustable IOL.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.